A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)
Clinical trial NCT02130466 · COMPLETED
Trial details
- NCT number
- NCT02130466
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-05-29
- Primary completion
- 2021-07-14
- Enrollment
- 184
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.